Concord Medical(US:CCM) Jin Rong Jie·2025-08-06 14:30Company Overview - Taihecheng Medical (CCM) experienced a 4.36% increase in stock price, reaching $5.27 per share, with a total market capitalization of $26.1483 million as of August 6 [1] - The company reported total revenue of 384 million RMB for the year ending December 31, 2024, representing a year-on-year decrease of 28.55% [1] - The net profit attributable to the parent company was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Business Operations - Taihecheng Medical Group Limited, listed on the New York Stock Exchange in 2009, focuses on medical services, particularly in cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihecheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research orientation, enhancing patient experience and improving cancer treatment standards in China [1]